In addition, we investigate potential mechanisms associated with LNRRIL6 and the IL‐6–STAT3 signaling pathway, crucial for determining the potential use of LNRRIL6 as a novel therapeutic target for CRC. The gene discussed is STAT3; the disease is colorectal carcinoma.